Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:01:18.796Z.
Calculation as of: 2026-10-06T12:01:18.796Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c158a84d2fb501edeaf3a566f8a4df3e38e32053a7ada5bbad4e1091841f2cc0
PE RATIO
N/A
Market Cap
$4.18M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09M
PE Ratio
N/A
TTM Avg
2856.01
3Y Avg
1890.61
5Y Avg
1890.61
Market Cap
$4.79M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.38M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baiya International Group Inc. (BIYA) | $3.78M | N/A | N/A | N/A | N/A |
| Addentax Group Corp. (ATXG)vs › | $3.51M | N/A | 1272.48 | 1592.69 | 1592.69 |
| Liberty Defense Holdings, Ltd. Common Shares (DETX)vs › | $4.18M | N/A | N/A | N/A | N/A |
| E-Power Inc. Class A (EPOW)vs › | $4.38M | N/A | N/A | N/A | N/A |
| BioNexus Gene Lab Corp. (BGLC)vs › | $3.09M | N/A | 2856.01 | 1890.61 | 1890.61 |
| FBS Global Limited Ordinary Shares (FBGL)vs › | $4.79M | N/A | N/A | N/A | N/A |
| DEFSEC Technologies Inc. (DFSC)vs › | $2.69M | N/A | N/A | N/A | N/A |
| Top KingWin Ltd. Class A (DPU)vs › | $2.64M | N/A | N/A | N/A | N/A |
| Cre8 Enterprise Limited Class A Ordinary Shares (CRE)vs › | $5.38M | N/A | N/A | N/A | N/A |
| Creative Global Technology Holdings Limited Ordinary Shares (CGTL)vs › | $5.89M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
